Zeposia Dosage

Cardiac Evaluation

Obtain an electrocardiogram (ECG) to determine whether preexisting conduction abnormalities are present. In patients with certain preexisting conditions, advice from a cardiologist should be sought.

Complete Blood Count

Obtain a recent (i.e., within the last 6 months or after discontinuation of prior MS or UC therapy) complete blood count (CBC), including lymphocyte count.

Liver Function Tests

Obtain recent (i.e., within the last 6 months) transaminase and bilirubin levels.

​Ophthalmic Assessment

​Obtain a baseline evaluation of the fundus, including the macula, near the start of treatment with ZEPOSIA.

​Skin Examination

​Obtain a baseline skin examination prior to or shortly after initiation of ZEPOSIA. If a suspicious skin lesion is observed, it should be promptly evaluated.

Current or Prior Medications

•

If patients are taking anti-neoplastic, non-corticosteroid immunosuppressive, or immune-modulating therapies, or if there is a history of prior use of these drugs, consider possible unintended additive immunosuppressive effects before initiating treatment with ZEPOSIA.

•

Determine if patients are taking drugs that could slow heart rate or atrioventricular conduction.

Vaccinations

Patients without a healthcare professional-confirmed history of chickenpox or without documentation of a full course of vaccination against varicella zoster virus (VZV) should be tested for antibodies to VZV before initiating ZEPOSIA; VZV vaccination of antibody-negative patients is recommended prior to commencing treatment with ZEPOSIA.

If live attenuated vaccine immunizations are required, administer at least 1 month prior to initiation of ZEPOSIA.